Approaches to harness the immune system to alleviate disease have become remarkably sophisticated since the crude, yet impressively-effective, attempts using live bacteria in the late 1800s. Recent evidence that engineered T cell therapy can deliver durable results in patients with cancer has spurred frenzied development in the field of T cell therapy. The myriad approaches include an innumerable variety of synthetic transgenes, multiplex gene-editing, and broader application to diseases beyond cancer. In this article, we review the preclinical studies and over a decade of clinical experience with engineered conventional T cells that have paved the way for translating engineered regulatory T cell therapies.

自从1800年代后期尝试使用活细菌进行粗制但效果显着的方法以来，利用免疫系统缓解疾病的方法已变得非常复杂。最近的证据表明，工程T细胞疗法可以为癌症患者带来持久的结果，这刺激了T细胞疗法领域的疯狂发展。无数的方法包括无数种合成的转基因，多重基因编辑以及对除癌症以外的疾病的广泛应用。在本文中，我们回顾了工程化常规T细胞的临床前研究和十多年的临床经验，这些传统T细胞为翻译工程化调节性T细胞疗法铺平了道路。